Loading…
Loading…
EQUITY / NASDAQ · XNCM
Intelligent Bio Solutions Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →07/01/2025 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.66 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.66 USD · Volume 43,704
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
07/01/2025 – 06/30/2026 · Units
| Metric | 2026 / Year end | 2025 / Year end | Change |
|---|---|---|---|
| Revenue | 4,215,175 USD | 3,052,532 USD | +38.09% |
| Operating profit | -12,608,085 USD | -10,679,158 USD | — |
| Net income | -12,430,975 USD | -10,568,733 USD | — |
| Operating cash flow | -11,927,222 USD | -9,677,313 USD | — |
| Cash and cash equivalents | 3,992,312 USD | 1,019,909 USD | +291.44% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Year end07/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Capital expendituresCash flow statement | 125,731 USD | — | 125,731 USD | — | 138,633 USD | — | 231,838 USD | — |
| Cash and cash equivalentsBalance sheet | 3,992,312 USD | 6,862,204 USD | — | — | — | — | 1,019,909 USD | 1,019,909 USD |
| Financing cash flowCash flow statement | 14,983,706 USD | — | 14,671,717 USD | — | 4,232,816 USD | — | 4,597,805 USD | — |
| Gross profitIncome statement | 2,049,994 USD | 535,381 USD | 1,513,411 USD | — | 978,030 USD | — | 1,246,859 USD | — |
| Investing cash flowCash flow statement | -85,573 USD | — | -85,573 USD | — | -98,475 USD | — | -231,838 USD | — |
| Net incomeIncome statement | -12,430,975 USD | -2,862,712 USD | -8,523,308 USD | -2,686,613 USD | -5,660,596 USD | -2,994,992 USD | -10,568,733 USD | — |
| Operating cash flowCash flow statement | -11,927,222 USD | — | -8,744,914 USD | — | -4,414,340 USD | — | -9,677,313 USD | — |
| Operating profitIncome statement | -12,608,085 USD | -2,947,101 USD | -8,639,350 USD | — | -5,635,331 USD | — | -10,679,158 USD | — |
| RevenueIncome statement | 4,215,175 USD | 1,060,802 USD | 3,069,373 USD | — | 2,008,571 USD | — | 3,052,532 USD | — |
| Total assetsBalance sheet | 11,941,836 USD | 14,862,792 USD | — | — | — | — | 8,249,786 USD | 8,249,786 USD |
| Total equityBalance sheet | 5,510,835 USD | 8,961,565 USD | — | 10,889,811 USD | — | 3,426,929 USD | 2,996,136 USD | 2,996,136 USD |
| Total liabilitiesBalance sheet | 6,651,010 USD | 6,111,476 USD | — | — | — | — | 5,435,962 USD | 5,435,962 USD |
| Report source | Open report ↗ Published: 08/19/2026 | Open report ↗ Published: 05/13/2026 | Open report ↗ Published: 05/13/2026 | Open report ↗ Published: 05/13/2026 | Open report ↗ Published: 02/12/2026 | Open report ↗ Published: 05/13/2026 | Open report ↗ Published: 08/19/2026 | Open report ↗ Published: 05/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.